First, regarding the good response to the inhibition of glutaminolysis in Sup-B15 and SEM cells, the central role of Gln in nucleotide, lipid, non-essential amino acid biosynthesis and others [30] has long been highlighted as a therapeutic target in cancer in general [19,30], including haematological malignancies (AML) [31,32], but not cALL in particular. The gene discussed is CHL1; the disease is acute myeloid leukemia.